medincell.com

Webside score medincell.com

Medincell - Impacting Global Health with Purposeful Innovation

 Genereret Maj 04 2026 08:46 AM

Gammel data? OPDATER !

Scoren er 54/100

SEO Indhold

Titel

Medincell - Impacting Global Health with Purposeful Innovation

Længde : 62

Perfekt, din titel indeholder mellem 10 og 70 bogstaver.

Beskrivelse

MedinCell creates better medicine for all through innovative long‑acting therapies that help improve global health.

Længde : 115

Perfekt, din meta beskrivelse indeholder mellem 70 og 160 karakterer.

Nøgleord

Dårligt! Vi kan ikke finde nogle meta nøgleord på din side! Brug denne gratis online meta generator for at oprette nye nøgleord.

Og Meta Egenskaber

Godt, din side benytter Og egenskaberne

Egenskab Indhold
url https://www.medincell.com/
site_name Medincell
locale en_US
locale:alternate fr_FR
type website
title Medincell - Impacting Global Health with Purposeful Innovation
description Join Medincell on a journey to transform global health with innovative therapies.
image https://www.medincell.com/wp-content/uploads/2026/02/Open_graph.jpg
image:secure_url https://www.medincell.com/wp-content/uploads/2026/02/Open_graph.jpg
image:width 1640
image:height 856
image:alt Logo de Medincell en bleu

Overskrifter

H1 H2 H3 H4 H5 H6
1 9 5 25 0 0
  • [H1] Impacting Global Health with Purposeful Innovation
  • [H2] Latest news & events
  • [H2] Improving health worldwide through new therapeutic options
  • [H2] Key figures
  • [H2] Products & R&D pipeline
  • [H2] mdc-TJK
  • [H2] mdc-CWM
  • [H2] Join the team
  • [H2] Corporate presentation
  • [H2] Get in touch
  • [H3] Products on market
  • [H3] UZEDY®
  • [H3] Programs in clinical phase 3
  • [H3] mdc-TJK
  • [H3] mdc-CWM
  • [H4] UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year
  • [H4] Degroof Petercam Initiates Medincell’s Coverage with a “Buy” Recommendation
  • [H4] Leerink Partners Initiates Medincell’s Coverage with a “Outperform” Recommendation
  • [H4] Medincell to Host an online R&D Day on Tuesday, May 12, 2026
  • [H4] 1
  • [H4] 2
  • [H4] 140
  • [H4] 25
  • [H4] U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
  • [H4] UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) ; OLANZAPINE LAI: EU Submission Expected in Q2 2026
  • [H4] Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
  • [H4] UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025
  • [H4] New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
  • [H4] Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
  • [H4] UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
  • [H4] UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025
  • [H4] Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI
  • [H4] Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia
  • [H4] Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM
  • [H4] Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
  • [H4] MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
  • [H4] MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
  • [H4] MedinCell: mdc-CWM clinical phase 3 will start in 2021
  • [H4] MedinCell provides a portfolio update for J.P. Morgan Healthcare Conference 2020
  • [H4] MedinCell announces that mdc-CWM progresses as planned

Billeder

Vi fandt 8 billeder på denne side.

4 alt tags mangler eller er tomme. Tilføj alternativ tekst til dine billeder for at gøre siden mere brugervenlig, og for at optimere din SEO i forhold til søgemaskinerne.

Text/HTML balance

Balance : 1%

Denne sides text til HTML fordeling er under 15 procent, dette betyder at din side mangler indhold!

Flash

Perfekt, ingen Flash objekter er blevet fundet på siden.

iFrame

Beklager! Din side har iFrames og det kan medføre i yderst dårlig læsning af søgerobotterne.

URL Omskrivning

Godt. Dine links ser venlige ud!

Underscores i links

Perfekt! Ingen underscores blev fundet i dine links

On-page links

Vi fandt et total af 30 links inkluderende 1 link(s) til filer

Anker Type Juice
Skip to main content Intern Sender Juice
Access Event Intern Sender Juice
Home Intern Sender Juice
See our R&D pipeline Intern Sender Juice
- Intern Sender Juice
See our open positions Intern Sender Juice
I have read and accept the privacy policy Intern Sender Juice
- Ekstern Sender Juice
- Ekstern Sender Juice
- Ekstern Sender Juice
Home Intern Sender Juice
About Us Intern Sender Juice
Impact company Intern Sender Juice
Our people Intern Sender Juice
Leadership team Intern Sender Juice
UZEDY® Intern Sender Juice
R&D Pipeline Intern Sender Juice
BEPO® Technology Intern Sender Juice
Publications Intern Sender Juice
Our commitments Intern Sender Juice
Code and policies Intern Sender Juice
2025 ESG Report Intern Sender Juice
Our vision & our values Intern Sender Juice
Work environment & benefits Intern Sender Juice
News Intern Sender Juice
Events Intern Sender Juice
Overview Intern Sender Juice
Regulated information Intern Sender Juice
General Meeting Intern Sender Juice
Contact Intern Sender Juice

SEO Nøgleord

Nøgleords cloud

news vision events benefits values environment search medincell team information

Nøgleords balance

Nøgleord Indhold Titel Nøgleord Beskrivelse Overskrifter
news 4
information 4
events 4
medincell 3
vision 3

Brugervenlighed

Link

Domæne : medincell.com

Længde : 13

FavIkon

Godt, din side har et FavIcon!

Printervenlighed

Vi kunne ikke finde en printer venlig CSS skabelon.

Sprog

Godt, dit tildelte sprog er en.

Dublin Core

Godt. Denne side benytter Dublin Core principperne.

Dokument

Dokumenttype

HTML 5

Kryptering

Perfekt. Dit Charset er tildelt UTF-8.

W3C Validering

Fejl : 0

Advarsler : 0

Email Privatliv

Godt! Ingen email adresser er blevet fundet i rå tekst!

Udgået HTML

Godt! Vi har ikke fundet udgåede HTML tags i din kildekode

Hastigheds Tips

Alle tiders! Din webside bruger ikke nestede tabeller.
Advarsel! Din webside benytter inline CSS kode!
Dårligt, din webside har for mange CSS filer (mere end 4).
Dårligt, din webside har for mange JavaScript filer (mere end 6).
Perfekt, din hjemmeside udnytter gzip.

Mobil

Mobil Optimering

Apple Ikon
Meta Viewport Tag
Flash indhold

Optimering

XML Sitemap

Stor, din hjemmeside har en XML sitemap.

https://www.medincell.com/sitemaps.xml

Robots.txt

https://medincell.com/robots.txt

Stor, din hjemmeside har en robots.txt-fil.

Analytics

Mangler

Vi har ikke registrerer en analyseværktøj installeret på denne hjemmeside.

Web analytics kan du måle besøgendes aktivitet på dit websted. Du bør have mindst én analyseværktøj installeret, men det kan også være godt at installere et sekund for at krydstjekke data.

PageSpeed Insights

Apparat
Kategorier

Free SEO Testing Tool

Free SEO Testing Tool er et gratis SEO redskab der hjælper med din hjemmeside